Trials / Completed
CompletedNCT05396235
A Clinical Pharmacology Study of MT-3921 in Healthy Adult Males
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 10 (actual)
- Sponsor
- Tanabe Pharma Corporation · Industry
- Sex
- Male
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to investigate the safety, tolerability, and pharmacokinetics when MT-3921 or a placebo is intravenously given to Japanese healthy adult male subjects
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | MT-3921 | Solution for infusion; Intravenous (IV) |
| BIOLOGICAL | Placebo | Solution for infusion; Intravenous (IV) |
Timeline
- Start date
- 2022-08-03
- Primary completion
- 2022-12-24
- Completion
- 2022-12-24
- First posted
- 2022-05-31
- Last updated
- 2023-01-18
Locations
1 site across 1 country: Japan
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05396235. Inclusion in this directory is not an endorsement.